LRRK2 kinase inhibitors (Imago Pharmaceuticals)

N/A

Report date: 2025/01/26 18:25:02
NME

Base Information

Drug NameLRRK2 kinase inhibitors (Imago Pharmaceuticals)
Drug Alias NameLRRK2 kinase inhibitors (Elan)LRRK2 kinase inhibitors (Perrigo)leucine-rich repeat kinase 2 kinase inhibitors (Elan)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesElan Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesImago Pharmaceuticals Inc
Inactive CompaniesPerrigo Company PlcElan Pharmaceuticals Inc
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A